ArticleBreast cancer research and treatment2018

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.

Tufia C Haddad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.